Literature DB >> 1675995

Medetomidine stereoisomers delineate two closely related subtypes of idazoxan (imidazoline) I-receptors in the guinea pig.

J E Wikberg1, S Uhlén, V Chhajlani.   

Abstract

A number of imidazoline, imidazole and guanidinium compounds and other drugs were compared for their ability to bind to non-adrenergic idazoxan (imidazoline) I-receptors in particulate guinea pig cerebral cortex and ileum smooth muscle fractions. Radioligand binding with [3H]idazoxan was used for the experiments. Computer modelling of the binding data gave dissociation constants for drug binding to both I-receptors and alpha 2-adrenoceptors. Most drugs showed similar affinities for I-receptors in cortex and ileum. However, medetomidine stereoisomers as well as a few other drugs clearly delineated the I-receptors in cortex and ileum as different.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675995     DOI: 10.1016/0014-2999(91)90148-j

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Delineation of three pharmacological subtypes of alpha 2-adrenoceptor in the rat kidney.

Authors:  S Uhlén; J E Wikberg
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

2.  Analysing the effect of I1 imidazoline receptor ligands on DSS-induced acute colitis in mice.

Authors:  Ágnes Fehér; Viktória E Tóth; Mahmoud Al-Khrasani; Mihály Balogh; Bernadette Lázár; Zsuzsanna Helyes; Klára Gyires; Zoltán S Zádori
Journal:  Inflammopharmacology       Date:  2016-11-21       Impact factor: 4.473

3.  Perioperative use of dexmedetomidine is associated with decreased incidence of ventricular and supraventricular tachyarrhythmias after congenital cardiac operations.

Authors:  Constantinos Chrysostomou; Joan Sanchez-de-Toledo; Peter Wearden; Edmund H Jooste; Steven E Lichtenstein; Patrick M Callahan; Tunga Suresh; Elizabeth O'Malley; Dana Shiderly; Jamie Haney; Masahiro Yoshida; Richard Orr; Ricardo Munoz; Victor O Morell
Journal:  Ann Thorac Surg       Date:  2011-09       Impact factor: 4.330

4.  Contrasting effects of the imidazol(in)e alpha 2-adrenoceptor agonists, medetomidine, clonidine and UK 14,304 on extraneuronal levels of noradrenaline in the rat frontal cortex: evaluation using in vivo microdialysis and synaptosomal uptake studies.

Authors:  J W Dalley; S C Stanford
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

5.  [3H]-idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2-type receptors: pharmacological characterization and relationship to monoamine oxidase.

Authors:  A Renouard; P S Widdowson; A Cordi
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

6.  Relevance of the use of [3H]-clonidine to identify imidazoline receptors in the rabbit brainstem.

Authors:  G Bricca; J Zhang; H Greney; M Dontenwill; J Stutzmann; A Belcourt; P Bousquet
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain.

Authors:  N J Mallard; A L Hudson; D J Nutt
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

8.  Effects of imidazolines on noradrenaline release in rat isolated kidney.

Authors:  C Bohmann; P Schollmeyer; L C Rump
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-02       Impact factor: 3.000

9.  A comparative study of the reversal by different alpha 2-adrenoceptor antagonists of the central sympatho-inhibitory effect of clonidine.

Authors:  C Vayssettes-Courchay; F Bouysset; A A Cordi; M Laubie; T J Verbeuren
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

10.  Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites.

Authors:  C A Brown; A C Loweth; S A Smith; N G Morgan
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.